Intratumoral IL-12/Flt3L mRNA-LNP therapy engages cDC1, NK and T cell immunity in checkpoint-resistant melanoma

Background Therapeutic resistance to immune checkpoint blockade in melanoma is frequently associated with defective dendritic cell licensing and impaired generation of durable tumor-reactive CD8 + T cell immunity. Local mRNA-LNP delivery provides a strategy to impose transient immunomodulatory programs within tumors while limiting systemic cytokine exposure. We investigated whether intratumoral co-administration of separately formulated IL-12 and Flt3L mRNA-LNPs could induce effective immunity in anti-PD-1-refractory melanoma. Methods Cytokine expression and immune activation were assessed in tumor cells, dendritic cells and macrophages. Therapeutic activity was evaluated in 5555 Braf V600E melanoma and B16F10 models, with or without anti-PD-1. Flow cytometry, RT-qPCR, ELISA, combined CD4/CD8 depletion, NK cell depletion, cDC1-deficient Irf8 +32kb−/− mice and BMDC/OT-I co-cultures were used to define immune responses and cellular requirements. Results Both formulations supported cytokine protein production. Co-administered IL-12/Flt3L mRNA-LNPs induced complete regressions and prolonged survival in 5555 melanoma, with or without anti-PD-1, and conferred protection against rechallenge. Benefit depended on treatment intensity. Treatment also prolonged survival in B16F10 melanoma, supporting activity in an additional model. On-treatment profiling identified local IL-12 p70 production, increased cDC1 prevalence, NK cell maturation and CD8 + T-cell activation. Loss of T cells, NK cells or cDC1s abolished therapeutic efficacy. In vitro, mRNA-LNP-conditioned BMDCs enhanced antigen-dependent OT-I activation and proliferation and altered TCF1–TIM3-defined T cell states. Conclusions Intratumoral co-administration of IL-12 and Flt3L mRNA-LNPs engages an endogenous cDC1- and lymphocyte-dependent response capable of controlling anti-PD-1-refractory melanoma. These findings support complementary, mRNA-based, local cytokine delivery as a strategy to coordinate innate and adaptive antitumor immunity.

Authors

Institutions

Publication Details

Journal
Journal of Experimental & Clinical Cancer Research
Published
2026-11-18
DOI
https://doi.org/10.1186/s13046-026-03879-0
Primary Topic
Immunotherapy and Immune Responses
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Intratumoral IL-12/Flt3L mRNA-LNP therapy engages cDC1, NK and T cell immunity in checkpoint-resistant melanoma

Aurora Gazzillo, Eduardo Bonavita, Camilla Volponi, Adriana Romanzi et al.
2 links
Journal of Experimental & Clinical Cancer Research
Immunotherapy and Immune Responses
article

Intratumoral IL-12/Flt3L mRNA-LNP therapy engages cDC1, NK and T cell immunity in checkpoint-resistant melanoma

Aurora Gazzillo, Eduardo Bonavita, Camilla Volponi, Adriana Romanzi, Cecília Garlanda, Andrea Gatta, Christian Simini
article en

Abstract

Background Therapeutic resistance to immune checkpoint blockade in melanoma is frequently associated with defective dendritic cell licensing and impaired generation of durable tumor-reactive CD8 + T cell immunity. Local mRNA-LNP delivery provides a strategy to impose transient immunomodulatory programs within tumors while limiting systemic cytokine exposure. We investigated whether intratumoral co-administration of separately formulated IL-12 and Flt3L mRNA-LNPs could induce effective immunity in anti-PD-1-refractory melanoma. Methods Cytokine expression and immune activation were assessed in tumor cells, dendritic cells and macrophages. Therapeutic activity was evaluated in 5555 Braf V600E melanoma and B16F10 models, with or without anti-PD-1. Flow cytometry, RT-qPCR, ELISA, combined CD4/CD8 depletion, NK cell depletion, cDC1-deficient Irf8 +32kb−/− mice and BMDC/OT-I co-cultures were used to define immune responses and cellular requirements. Results Both formulations supported cytokine protein production. Co-administered IL-12/Flt3L mRNA-LNPs induced complete regressions and prolonged survival in 5555 melanoma, with or without anti-PD-1, and conferred protection against rechallenge. Benefit depended on treatment intensity. Treatment also prolonged survival in B16F10 melanoma, supporting activity in an additional model. On-treatment profiling identified local IL-12 p70 production, increased cDC1 prevalence, NK cell maturation and CD8 + T-cell activation. Loss of T cells, NK cells or cDC1s abolished therapeutic efficacy. In vitro, mRNA-LNP-conditioned BMDCs enhanced antigen-dependent OT-I activation and proliferation and altered TCF1–TIM3-defined T cell states. Conclusions Intratumoral co-administration of IL-12 and Flt3L mRNA-LNPs engages an endogenous cDC1- and lymphocyte-dependent response capable of controlling anti-PD-1-refractory melanoma. These findings support complementary, mRNA-based, local cytokine delivery as a strategy to coordinate innate and adaptive antitumor immunity.

Journal of Experimental & Clinical Cancer Research
Humanitas University (IT), Fondazione Humanitas per la Ricerca (IT), IRCCS Humanitas Research Hospital (IT)
Good health and well-being
Immunotherapy and Immune Responses
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon